Day-one subcutaneous Leqembi allows eligible people with early Alzheimer's to start treatment with weekly injections at home in 2026. Leqembi is an anti-amyloid drug, a medicine that targets amyloid protein buildup in the brain. Home start removes infusion visits but keeps MRI checks and safety vigilance.
Eisai and Biogen announced FDA approval of this subcutaneous starter for early Alzheimer's in July 2026, Eisai July 2026 approval announcement. The practical question for patients is not where the shot happens. It is who qualifies, what risks remain, and what monitoring still applies.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What day-one injections change
- Who may start this treatment?
- What are the main safety risks?
- What monitoring continues at home?
What day-one injections change
The starter regimen is 500 mg once weekly, given as two consecutive 250-mg autoinjector injections of about 15 seconds each. Patients or care partners can give the shots at home after training. Eisai U.S. reported the autoinjector for initiation became available in the U.S. in August 2026, Eisai U.S.
August 2026 availability update. After 18 months of initiation treatment by IV or injection, patients may switch to 360 mg once-weekly maintenance injections. This day-one option expands an earlier approach. FDA had allowed weekly subcutaneous maintenance only after 18 months of IV Leqembi. That change made home dosing possible, but only for patients who first completed long IV treatment.
Who may start this treatment?
Leqembi is for early disease only. That means mild cognitive impairment or mild dementia with confirmed amyloid pathology. It is not for moderate or advanced dementia. Confirmation of amyloid matters because treatment targets amyloid in the brain.
A memory clinic can explain the tests used to confirm amyloid. Genotype testing is also required before starting. Care partners play a central role in a home-start plan. They can help track doses, appointments, and new symptoms. They can also help decide whether home injections fit daily life.
What are the main safety risks?
The FDA-approved labeling carries a boxed warning for amyloid-related imaging abnormalities, called ARIA, FDA-approved labeling record. ARIA includes swelling or fluid buildup, called edema, and bleeding, called hemorrhage. Events can be serious and fatal. People with two copies of the ApoE e4 gene face higher ARIA risk.
That gene variant affects how the body handles amyloid. Testing before treatment helps patients and doctors weigh risk. Home dosing does not make the drug milder. The same safety questions apply as with clinic treatment. A new headache, confusion, or fall still needs fast medical review.
What monitoring continues at home?
Patients still need a baseline MRI and scheduled follow-up MRIs. FDA recommended an earlier MRI check between the second and third doses to find ARIA-related swelling sooner, FDA August 2025 safety communication. MRI results guide whether to pause or stop treatment.
At home, families should watch for warning signs and seek prompt care: Keep a simple log with dose dates, MRI dates, and symptoms. Bring it to each visit and call the care team right away for concerning changes. Do not wait for the next MRI if symptoms appear.
- new or worse headache
- confusion, trouble thinking, or behavior change
- dizziness, trouble walking, or fainting
- vision changes, nausea, or seizure-like activity
You Might Also Like
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
